^
    3ms
    NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov)
    P1, N=221, Terminated, M.D. Anderson Cancer Center | Trial completion date: Dec 2024 --> Sep 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Sep 2024; Administratively Complete
    Trial completion date • Trial termination • Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • Yervoy (ipilimumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • pemetrexed • oxaliplatin • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • daunorubicin • topotecan • leucovorin calcium • fluorouracil topical • Pemfexy (pemetrexed)
    4ms
    ENDURE: Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (clinicaltrials.gov)
    P2, N=51, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Sep 2024 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    5ms
    Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (clinicaltrials.gov)
    P3, N=304, Recruiting, National Cancer Institute (NCI) | Initiation date: Nov 2024 --> Jul 2024
    Trial initiation date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    6ms
    Lung-MAP Sub-Study: Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2; N=74 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    FoundationOne® CDx
    |
    carboplatin • Retevmo (selpercatinib) • pemetrexed • Pemfexy (pemetrexed)
    6ms
    Lung-MAP Sub-Study: Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2; Trial primary completion date: May 2028 --> Jun 2023
    Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    FoundationOne® CDx
    |
    carboplatin • Retevmo (selpercatinib) • pemetrexed • Pemfexy (pemetrexed)
    9ms
    Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=42, Recruiting, National Cancer Institute (NCI) | N=78 --> 42
    Enrollment change • Combination therapy
    |
    CD4 (CD4 Molecule)
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • Pemfexy (pemetrexed) • methoxyamine (TRC102)
    10ms
    EA5163: Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=600, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • Pemfexy (pemetrexed)
    10ms
    Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (clinicaltrials.gov)
    P3, N=304, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Feb 2024 --> Nov 2024
    Enrollment open • Trial initiation date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK translocation • EGFR negative
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    10ms
    Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, M.D. Anderson Cancer Center | Phase classification: P1b --> P1
    Phase classification • Combination therapy
    |
    Avastin (bevacizumab) • carboplatin • pemetrexed • Ensacove (ensartinib) • Pemfexy (pemetrexed)
    11ms
    Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=18, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Dec 2023 | Trial primary completion date: Jun 2024 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date • Surgery
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • etoposide IV • Pemfexy (pemetrexed)
    12ms
    NEOSTAR: Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=101, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker • Checkpoint block
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • docetaxel • pemetrexed • Pemfexy (pemetrexed)
    12ms
    Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Surgery
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • etoposide IV • Pemfexy (pemetrexed)
    1year
    Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=28, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Pemfexy (pemetrexed) • papaverine
    1year
    Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib (clinicaltrials.gov)
    P2, N=0, Withdrawn, SCRI Development Innovations, LLC | N=15 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Combination therapy • Metastases
    |
    cisplatin • carboplatin • Lorbrena (lorlatinib) • pemetrexed • Pemfexy (pemetrexed)
    1year
    Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) (clinicaltrials.gov)
    P3; N=975; Recruiting; Sponsor:Daiichi Sankyo, Inc.
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • datopotamab deruxtecan (DS-1062a) • Pemfexy (pemetrexed)
    1year
    Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2024 --> Sep 2024
    Trial completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    ALK positive • MET amplification • ALK rearrangement
    |
    cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)
    1year
    Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (clinicaltrials.gov)
    P3, N=304, Not yet recruiting, National Cancer Institute (NCI)
    New P3 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK translocation • EGFR negative
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    1year
    G360-IIT: Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (clinicaltrials.gov)
    P2; Not yet recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • Guardant360® CDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    1year
    Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Vanderbilt-Ingram Cancer Center | Suspended --> Recruiting
    Enrollment open • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    1year
    Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer (clinicaltrials.gov)
    P1/2, N=25, Suspended, Vanderbilt-Ingram Cancer Center | Recruiting --> Suspended
    Trial suspension • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    over1year
    Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases (clinicaltrials.gov)
    P2, N=35, Recruiting, Liza Villaruz, MD | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Apr 2027 | Initiation date: May 2023 --> Aug 2023 | Trial primary completion date: May 2025 --> Sep 2025
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058) • Pemfexy (pemetrexed)
    over1year
    Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib (clinicaltrials.gov)
    P2, N=15, Not yet recruiting, SCRI Development Innovations, LLC
    New P2 trial • Combination therapy • Metastases
    |
    cisplatin • carboplatin • Lorbrena (lorlatinib) • pemetrexed • Pemfexy (pemetrexed)
    over1year
    Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=50 --> 18
    Enrollment closed • Enrollment change • Surgery
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • etoposide IV • Pemfexy (pemetrexed)
    over1year
    NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=221, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=390 --> 221 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • Yervoy (ipilimumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • pemetrexed • oxaliplatin • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • daunorubicin • topotecan • leucovorin calcium • fluorouracil topical • Pemfexy (pemetrexed)
    over1year
    NEOSTAR: Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=101, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
    Trial completion date • Trial primary completion date • Checkpoint inhibition • Checkpoint block
    |
    CD8 (cluster of differentiation 8)
    |
    CD8 positive
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • docetaxel • pemetrexed • Pemfexy (pemetrexed)
    over1year
    Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=474, Recruiting, NRG Oncology | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • ALK mutation
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV • Pemfexy (pemetrexed)
    over1year
    Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Oct 2026 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Feb 2026
    Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    over1year
    Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (clinicaltrials.gov)
    P2/3, N=82, Active, not recruiting, SWOG Cancer Research Network | Recruiting --> Active, not recruiting | N=478 --> 82
    Enrollment closed • Enrollment change • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • ALK fusion • ROS1 fusion • MET mutation • NTRK fusion
    |
    Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln) • Hemady (dexamethasone tablets) • Pemfexy (pemetrexed)
    over1year
    Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Liza Villaruz, MD | Trial completion date: Dec 2028 --> Dec 2026 | Trial primary completion date: Dec 2025 --> May 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058) • Pemfexy (pemetrexed)
    almost2years
    Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=846, Recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2023 --> Dec 2028 | Trial primary completion date: Sep 2023 --> Dec 2028
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • Pemfexy (pemetrexed)
    almost2years
    Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative (clinicaltrials.gov)
    P2/3, N=427, Recruiting, National Cancer Institute (NCI) | N=100 --> 427
    Enrollment change • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK mutation • ROS1 mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    almost2years
    Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Vanderbilt-Ingram Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    almost2years
    Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Liza Villaruz, MD
    New P2 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058) • Pemfexy (pemetrexed)
    almost2years
    G360-IIT: Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (clinicaltrials.gov)
    P2; N=108; Not yet recruiting; Sponsor:Hackensack Meridian Health
    New P2 trial • Circulating tumor DNA • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • Guardant360® CDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    almost2years
    GEOMETRY-E: Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (clinicaltrials.gov)
    P3, N=6, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; Novartis decided to halt enrolment for this study on 11-May-2022. This decision was based on a business decision and not related with any safety concerns.
    Trial termination • Combination therapy • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • EGFR T790M negative
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Tabrecta (capmatinib) • Pemfexy (pemetrexed)
    almost2years
    AVANZAR: Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=1000, Recruiting, AstraZeneca
    New P3 trial • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    EGFR mutation • ALK rearrangement • ROS1 rearrangement • TROP2 positive
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • datopotamab deruxtecan (DS-1062a) • Pemfexy (pemetrexed)
    almost2years
    Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) (clinicaltrials.gov)
    P3; Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • datopotamab deruxtecan (DS-1062a) • Pemfexy (pemetrexed)
    2years
    ENDURE: Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (clinicaltrials.gov)
    P2, N=51, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Trial completion date: Sep 2022 --> Sep 2024 | Trial primary completion date: Sep 2022 --> Sep 2024
    Enrollment open • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement
    |
    carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    2years
    Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=474, Not yet recruiting, NRG Oncology
    New P3 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • EGFR mutation • ALK mutation
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV • Pemfexy (pemetrexed)
    2years
    GEOMETRY-E: Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (clinicaltrials.gov)
    P3, N=6, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: May 2022 --> Dec 2022
    Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • EGFR T790M negative
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Tabrecta (capmatinib) • Pemfexy (pemetrexed)
    2years
    NEOSTAR: Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=101, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition • Checkpoint block
    |
    CD8 (cluster of differentiation 8)
    |
    CD8 positive
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • docetaxel • pemetrexed • Pemfexy (pemetrexed)
    2years
    Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer (clinicaltrials.gov)
    P1/2, N=25, Not yet recruiting, Vanderbilt-Ingram Cancer Center | Initiation date: Sep 2022 --> Jan 2023
    Trial initiation date • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)